Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.70548
Abstract: Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse Event… read more here.
Keywords: event reporting; fda adverse; reporting system; adverse event ... See more keywords
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00632-w
Abstract: BackgroundImmune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death 1 or its ligand (PD1/PDL1), elicit different immune-related adverse events (irAEs), but their global safety is incompletely characterized.ObjectiveThe… read more here.
Keywords: reporting; checkpoint inhibitors; disproportionality; pd1 pdl1 ... See more keywords
Decrease in therapeutic effect among botulinum neurotoxin type A agents: Analysis of the fda adverse event reporting system database
Sign Up to like & getrecommendations! Published in 2018 at "Toxicon"
DOI: 10.1016/j.toxicon.2018.11.141
Abstract: • There are three FDA (Food and Drug Administration) approved botulinum toxin type A (BoNT-A) agents: onabotulinumtoxinA (Botox; Allergan, Inc.; initial FDA approval 1989), abobotulinumtoxinA (Dysport; Galderma Laboratories, L.P. for cosmetic; initial FDA approval 2009),… read more here.
Keywords: adverse event; effect; fda adverse; type ... See more keywords
Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-10924-z
Abstract: Cataract is a leading cause of irreversible vision loss, particularly among the elderly, with drug-induced cataract being an underrecognized yet significant contributor to visual impairment. This study investigates the associations between medications and cataract development… read more here.
Keywords: event reporting; cataract; fda adverse; drug induced ... See more keywords
A disproportionality analysis of FDA adverse event reporting system events for misoprostol
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-86422-z
Abstract: Misoprostol was originally used to treat gastric ulcers, and has been widely used in abortion, cervical maturation, induced labour and postpartum hemorrhage. But there are still many undetected adverse events (AEs). The purpose of this… read more here.
Keywords: system; adverse events; fda adverse; event ... See more keywords
A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-89632-7
Abstract: To explore and analyze the potential adverse event (AE) signals of trazodone, with reference to the safe clinical use of drugs. Based on the FDA Adverse Event Reporting System (FAERS), the AE data of trazodone… read more here.
Keywords: event reporting; trazodone; fda adverse; based fda ... See more keywords
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton’s tyrosine kinase inhibitors (BTKis) single and its combination therapy
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2327507
Abstract: ABSTRACT Background Bruton’s tyrosine kinase inhibitors (BTKis) are targeted treatments for B-cell tumors but have significant side effects. This study assesses and contrasts the side effects of BTKis alone and its four combination therapies. Research… read more here.
Keywords: fda adverse; inhibitors btkis; tyrosine kinase; adverse event ... See more keywords
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2396392
Abstract: ABSTRACT Background The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information. Research design and methods We reviewed all the ED reports… read more here.
Keywords: drug induced; fda adverse; drug; erectile dysfunction ... See more keywords
Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2405126
Abstract: ABSTRACT Background Drug-induced urinary retention (DIUR) can severely impact patient quality of life and complicate treatment. This study investigates the incidence and characteristics of DIUR using data from the FDA Adverse Event Reporting System (FAERS)… read more here.
Keywords: urinary retention; fda adverse; drug induced; induced urinary ... See more keywords
Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database.
Sign Up to like & getrecommendations! Published in 2024 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2024.2418325
Abstract: BACKGROUND The increasing prevalence of statin use for cardiovascular disease management has raised concerns regarding their safety profile, particularly regarding the potential risk of diabetes. Our study aims to analyze diabetic adverse event reports related… read more here.
Keywords: adverse events; fda adverse; disproportionality; adverse event ... See more keywords
Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting system
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2421340
Abstract: ABSTRACT Background Levetiracetam, a widely prescribed antiseizure medication, is recognized for its broad-spectrum efficacy, good tolerability, and minimal drug interactions. This study examines the association between levetiracetam and rhabdomyolysis, utilizing real-world data from the FDA… read more here.
Keywords: fda adverse; real world; risk; adverse event ... See more keywords